Compare GSK plc (GSK) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Robinhood Markets, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B). The key difference: GSK plc and Robinhood Markets, Inc. are close in size by market cap, and GSK plc pays a 3.9% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Robinhood Markets, Inc. for 75 Days on average.
| GSK | HOOD | |
|---|---|---|
Market Cap | $91.88B | $96.21B |
Volume | 7,730,529 | 22,572,153 |
Sector | Health | Financials |
52-Week High | $61.18 | $152.46 |
52-Week Low | $43.24 | $65.16 |
Typical Hold Time | 93 Days | 75 Days |
Enterprise Value | $111.88B | $102.75B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Robinhood (HOOD) trades at $107.01, down 2.28% today, amid a bullish technical setup with support at $105 and resistance at $109. The company reported strong 2025 results with revenue of $4.47 billion and net income of $1.88 billion, though Q1 2026 earnings missed expectations. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at boosting engagement.
Outlook remains positive with a consensus price target of $137.53, implying 28% upside, supported by 77% analyst buy ratings. Key risks include high valuation multiples (P/E 47.35) and reliance on retail trading growth, while regulatory scrutiny and market volatility pose challenges to sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
